

23rd April 2007

INFORMATION NOTE: CYSTIC FIBROSIS DRUGS: INTERFACE ISSUES

Could you please disseminate to the appropriate individuals within your organisation

Dear Colleague

Use of tobramycin and dornase alfa for adults with cystic fibrosis.

I refer you to the attached AWMSG Enclosures No. **6/AWMSG/0307** and **3/AWMSG/1206** in relation to the prescribing of nebulised tobramycin and dornase alfa for adults with cystic fibrosis. An 'opt-in approach' was suggested by the All Wales Prescribing Advisory Group which would provide a stable, non-binding approach to support professionals wishing to prescribe these drugs under shared care arrangements, **recognising that this would be subject to local agreement**. This principle and attached templates have been endorsed by the All Wales Medicines Strategy Group at their meeting in March 2007. This decision was reached following extensive multi-professional consultation across the primary, secondary and tertiary sectors.

This information note has been prepared by the AWMSG Secretariat to support the **draft minutes** of the AWMSG Meeting held in March 2007.

Yours sincerely

Philip A. Routledge
Acting AWMSG Chairman